Dati del progetto
|
Principal Investigator |
Dr.ssa Monica Locatelli |
|
Ente ospitante |
Istituto di Ricerche Farmacologiche Mario Negri IRCCS |
|
Area Tematica |
Malattie Rare |
|
Data di inizio Progetto |
16/12/2024 |
|
Data di fine Progetto |
15/12/2027 |
|
Importo assegnato |
494.920,00 € |
|
Tipo Progetto |
Individuale |
PROJECT AIMS
Anti-neutrophil cytoplasmic antibodies associated vasculitis (AAV) is a group of rare lifethreatening systemic disorders. Its management involves an immunosuppressive-based approach, not always entirely effective, leading to relapses and highlighting the need for newer therapies. Our preliminary and published data indicate that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) can offer immunomodulatory, renal, and cardio-protective benefits. The primary goal of the project is to investigate the role and the pharmacological potential of the SGLT-2 targeting in AAV through a multidisciplinary approach.